Treatment of SARS-CoV-2 (COVID-19): A safety perspective

Table 1 Summary of guideline recommendations for COVID-19 treatment

Organization	Dexamethasone	Hydroxychloroquine	Remdesivir	Convalescent plasma	Tocilizumab
World Health Organization	Strong recommendation to use in patients with severe/critical illness; Conditional recommendation against use in non-severe/critical patients	Strong recommendation against use	Conditional recommendation against use	No recommendation	No recommendation
United States Centers for Disease Control and Prevention/National Institutes of Health	Recommend use in patient requiring supplemental oxygen or mechanical ventilation; Recommend against use in patients not requiring supplemental oxygen	Recommend against	Recommend in hospitalized patients requiring supplemental oxygen; Not routinely recommended for patients requiring mechanical ventilation	Recommends against use in hospitalized patients; No recommendation for non-hospitalized or immunocompromised patients	Recommended for patients requiring mechanical ventilation within 24 h of ICU admission
Infectious Disease Society of America	Suggest against use in hospitalized patients not requiring oxygen; Suggest use for patients with severe disease; Recommend use for patients with critical disease	Recommend against use	Suggest against use in hospitalized patients not requiring oxygen; Suggest use for patients with severe/critical disease	Suggest against use	Conditionally suggest use in severe/critical patients
Surviving Sepsis/Society for Critical Care Medicine	Recommend for patients with severe/critical illness	Recommend against use in patients with severe/critical illness	Recommend to use in severe/critical patients not receiving mechanical ventilation; Recommend against starting in patients receiving mechanical ventilation	Recommend against (outside of clinical trial) for patients with severe/critical illness	No recommendation